INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma-Reference-Cited by-同舟云学术

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

Published:2019-05 Issue:13 Volume:15 Page:1411-1428
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Costello Caitlin¹,Davies Faith E²,Cook Gordon³,Vela-Ojeda Jorge⁴,Omel Jim⁵,Rifkin Robert M⁶,Berdeja Jesus⁷,Puig Noemi⁸,Usmani Saad Z⁹,Weisel Katja¹⁰¹¹,Zonder Jeffrey A¹²,Terpos Evangelos¹³,Spencer Andrew¹⁴,Leleu Xavier¹⁵,Boccadoro Mario¹⁶,Thompson Michael A¹⁷,Romanus Dorothy¹⁸,Stull Dawn M¹⁹,Hungria Vania²⁰

Affiliation:

1. Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA

2. Myeloma Institute, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA

3. Department of Haematology, Leeds Cancer Centre, St James's University Hospital, Leeds, UK

4. Hematology Department, La Raza Medical Center, IMSS, México City, México

5. The Central Nebraska Myeloma Support Group, Grand Island, NE 68801, USA

6. Department of Hematology Research, US Oncology Research/Rocky Mountain Cancer Centers, Denver, CO 80218, USA

7. Department of Hematology, Sarah Cannon Research Institute, Nashville, TN 37203, USA

8. Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain

9. Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC 28204, USA

10. Department of Hematology, University of Tuebingen, Tuebingen, Germany

11. Department of Oncology, Hematology & Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

12. Department of Oncology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI 48201, USA

13. Department of Clinical Therapeutics, National & Kapodistrian University of Athens, School of Medicine, Athens, Greece

14. Department of Clinical Haematology, Alfred Health-Monash University, Melbourne, Australia

15. Pôle Régional de Cancérologie and CIC1402 INSERM, CHU de Poitiers, France

16. Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

17. Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI 53215, USA

18. Global Outcomes Research, Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA

19. Global Medical Affairs, Millenium Pharmaceuticals, Inc., Cambridge, MA 02139, USA

20. Department of Hematology, Clinica São Germano and Santa Casa Medical School, São Paulo, Brazil

Abstract

With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients’ outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients. Trial registration number: NCT02761187

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2019-0013

Reference59 articles.

1. Cancer statistics, 2018

2. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018

3. National Cancer Institute SEER, Cancer Statistics Review, 1975–2015 (2018). https://seer.cancer.gov/csr/1975_2015/results_merged/sect_18_myeloma.pdf.

4. Cancer Research UK. Myeloma survival statistics (2014). www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/survival#heading-Two.

5. Office for National Statistics. Cancer survival in England: adult, stage at diagnosis and childhood – patients followed up to 2016 (2015). www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalinengland/adultstageatdiagnosisandchildhoodpatientsfollowedupto2016#cancer-survival-in-england-patients-diagnosed-between-2011-and-2015-and-followed-up-to-2016-national-statistics.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice;Future Oncology;2024-01-10

2. The Singular Epidemiology of Plasmacytoma and Multiple Myeloma in French Guiana;Cancers;2023-12-29

3. Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study;Cancers;2023-12-14

4. Glycosylation as regulator of human B-cell leukaemias in bone marrow;Frontiers in Hematology;2023-11-16

5. In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma;Future Oncology;2023-10-09